Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A paper on a therapeutic cancer vaccine from the Van den Eynde lab was singled out for this award celebrating excellence in scientific research.

Each year, the Journal for ImmunoTherapy of Cancer announces awards for the best papers published in the journal in five different categories. These awards “celebrate excellence in scientific research” and are awarded to “researchers demonstrating leadership in the field as well as innovation and high-quality execution and discussion in their manuscripts”.

A paper led by Dr James McAuliffe from Ludwig Oxford’s Van den Eynde laboratory has won the 2022 award for the best basic tumour immunology paper.

This research demonstrated that the technology behind the Oxford-AstraZeneca COVID-19 vaccine has potential in treating cancer. In pre-clinical models, the team showed that a viral vector cancer vaccine generates effective anti-tumour immune responses and, in combination with immunotherapy, decreases tumour size and increases survival rates. A first-in-human clinical trial of the therapeutic cancer vaccine in patients with non-small cell lung cancer dosed its first patient earlier this year.

The winning paper can be read on the Journal for ImmunoTherapy of Cancer website.

Similar stories

Ludwig Oxford at 2024 AACR

Ludwig Oxford staff and students alike share their research in San Diego at the 2024 AACR Annual Meeting